Literature DB >> 508942

Effect of prothrombin complex concentrates on factor VIII inhibitor levels.

C K Kasper.   

Abstract

Factor VIII inhibitor levels were measured on 261 occasions in 76 hemophilia-A inhibitor patients before and after prothrombin complex concentrate infusion at 13 treatment centers. A rise in inhibitor level to at least twice the pretreatment value occurred in 35 treatment episodes (13.5%), in 27 patients (36%). In 16 patients (21%), such an anamnestic immune response occurred with the first treatment. Factors predisposing to anamnestic responses may include patient idiosyncrasy, low pretreatment inhibitor levels, and exposure to concentrate over several days.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 508942

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  3 in total

Review 1.  Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomes.

Authors:  Amy D Shapiro; Ulla Hedner
Journal:  Ther Adv Drug Saf       Date:  2011-10

2.  Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.

Authors: 
Journal:  CMAJ       Date:  1995-07-15       Impact factor: 8.262

Review 3.  Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors.

Authors:  Geir E Tjønnfjord; Pål Andre Holme
Journal:  Vasc Health Risk Manag       Date:  2007
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.